KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Cash from Financing Activities (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Cash from Financing Activities data on record, last reported at -$11.4 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 139.86% year-over-year to -$11.4 million; the TTM value through Dec 2025 reached -$956.8 million, up 2.67%, while the annual FY2025 figure was -$956.8 million, 2.67% up from the prior year.
  • Cash from Financing Activities reached -$11.4 million in Q4 2025 per EW's latest filing, up from -$740.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $61.7 million in Q1 2024 and bottomed at -$976.7 million in Q3 2024.
  • Average Cash from Financing Activities over 5 years is -$229.6 million, with a median of -$120.0 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: plummeted 1252.26% in 2022, then soared 154.55% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$62.0 million in 2021, then tumbled by 1252.26% to -$838.4 million in 2022, then soared by 50.72% to -$413.2 million in 2023, then surged by 106.92% to $28.6 million in 2024, then plummeted by 139.86% to -$11.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$11.4 million in Q4 2025, -$740.1 million in Q3 2025, and $52.7 million in Q2 2025.